Enfortumab vedotin therapy complicated by bullous dermatitis: A case report

Enfortumab vedotin therapy complicated by bullous dermatitis: A case report

Saved in:

Bibliographic Details
Main Authors:	Roxana A. Hojjatie, BS, Haya S. Raef, MD, Taha O. Mohammed, MD, Emily Henkel, MD, Zachary Wolner, MD
Format:	Article
Language:	English
Published:	Elsevier 2025-07-01
Series:	JAAD Case Reports
Subjects:	adverse drug reaction autoimmune blistering diseases bullous dermatitis enfortumab
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352512625001547
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Use of dupilumab to manage a grade 3 cutaneous adverse effect from enfortumab vedotin/pembrolizumab treatment in a patient with metastatic urothelial carcinoma
by: Maura C. Gillis, BA, et al.
Published: (2025-02-01)

Recognition and management of adverse cutaneous reactions in patients on enfortumab vedotin and pembrolizumab in the inpatient setting
by: Emma L. Myers, BA, et al.
Published: (2025-04-01)

Direct immunofluorescence in bullous disorders: A mini-review
by: Anil Dev Pant
Published: (2024-10-01)

Lung Toxicity Occurring During Enfortumab Vedotin Treatment: From a Priming Case Report to a Retrospective Analysis
by: Grégoire Desimpel, et al.
Published: (2024-11-01)

Efficacy of modified enfortumab vedotin ineligible criteria (mEVITA) in advanced urothelial carcinoma
by: Takafumi Fukushima, et al.
Published: (2025-07-01)

Localized genital blisters in an elderly male
by: An Jian Leung, MBBS, MRCP, MMed, et al.
Published: (2025-05-01)

Bullous Pemphigoid and Epidemiological Patterns in Northern Greece: Insights from an 8-Year Observational Study
by: Athina-Ioanna Daponte, et al.
Published: (2025-04-01)

Dramatic Response to Enfortumab Vedotin in Soft-tissue Metastases from Urothelial Carcinoma: A Case Report
by: Ming-Hsuan Wu, et al.
Published: (2024-12-01)

Oral Manifestations of Bullous Systemic Lupus Erythematosus: A Systematic Review
by: Gabrielle Keller Goff, et al.
Published: (2025-07-01)

Enfortumab Vedotin–Induced Toxic Epidermal Necrolysis in Metastatic Urothelial Carcinoma Complicated by Severe Gastrointestinal Bleeding
by: Aika Matsuyama, et al.
Published: (2025-07-01)

Strategies to overcome resistance to enfortumab vedotin and pembrolizumab for patients with urothelial carcinoma: harnessing present knowledge for future advances
by: Albert Jang, et al.
Published: (2025-04-01)

Iridoschisis in patients with atopic dermatitis leads to intractable bullous keratopathy
by: Yuki Kusano, et al.
Published: (2025-07-01)

Venous thromboembolism in bullous pemphigoid: current evidence and update on systematic review
by: Atheer G. Almutairi, et al.
Published: (2025-01-01)

Real‐Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON‐2 Retrospective Experience
by: Mimma Rizzo, et al.
Published: (2025-02-01)

Delayed diagnosis of pemphigus herpetiformis in a patient with dupilumab-associated hypereosinophilia
by: Sarah E. Smith, MD, et al.
Published: (2025-08-01)

Localization of Lesions in Autoimmune Blistering Diseases Is Independent of Site-Specific Target Antigen Expression
by: Tina Rastegar Lari, et al.
Published: (2025-01-01)

Bullous pemphigoid and morphea: Coexistence or an incidental association
by: Seema Rani, et al.
Published: (2024-12-01)

First experience in treating advanced urothelial cancer with enfortumab vedotin. Single-centre retrospective study of patients qualified for a rescue access procedure
by: Bożena Sikora-Kupis, et al.
Published: (2024-01-01)

Severe cutaneous toxicity in a 67-year-old patient with metastatic urothelial carcinoma undergoing therapy with enfortumab vedotin and pembrolizumab
by: Benjamin Müller, et al.
Published: (2024-11-01)

Pemphigoid diseases as immune-related adverse effect following immune checkpoint inhibitors: A clinical case series of a diverse spectrum
by: Nika Kotnik, MD, et al.
Published: (2025-07-01)

Mechanistic Insights and Future Directions for Enfortumab Vedotin in Urothelial Carcinoma: Highlights from the 10th Annual Leo & Anne Albert Institute for Bladder Cancer Care and Research Symposium
by: Catherine C. Fahey, et al.
Published: (2025-05-01)

Enfortumab vedotin induced interstitial lung disease: A first case report with pathological evidence from transbronchial lung cryobiopsy
by: Shota Kaburaki, et al.
Published: (2025-01-01)

HLA-Cw6 Polymorphism in Autoimmune Blistering Diseases
by: Christian Ciolfi, et al.
Published: (2024-09-01)

Diagnosing Autoimmune Bullous Diseases—An Indian Perspective
by: Adhyatm Bhandari, et al.
Published: (2025-05-01)

Features of polymorbid pathology in patients with autoimmune bullous dermatosis
by: M. A. Ufimtseva, et al.
Published: (2021-01-01)

JAK-STAT pathway, type I/II cytokines, and new potential therapeutic strategy for autoimmune bullous diseases: update on pemphigus vulgaris and bullous pemphigoid
by: Xiaoying Lin, et al.
Published: (2025-04-01)

A rare clinical presentation of dermatitis herpetiformis with blisters principally on elbows: a report of three female cases
by: Magdalena Jałowska, et al.
Published: (2025-01-01)

Atypical bullous systemic lupus erythematosus with features of linear IgA bullous dermatosis
by: Roy Jiang, MD, PhD, et al.
Published: (2025-04-01)

A Narrative Review of Pemphigoid Diseases: Bridging Associations, Comorbidities, and Management
by: Emma L. Myers, et al.
Published: (2025-05-01)

A histopathological overlap of linear IgA bullous dermatosis and vasculitis
by: Tharani Murali, MHS, et al.
Published: (2025-02-01)

Autoimmune bullous diseases: pathogenesis and clinical management
by: Xun Feng, et al.
Published: (2025-05-01)

Case report: Low-dose interleukin-2: a treatment of bullous pemphigoid with predominantly perifollicular blistering caused by PD-1/PD-L1 inhibitor
by: Yingyue Zhang, et al.
Published: (2024-12-01)

Linear IgA bullous dermatosis: 32 years of experience
by: Tugba Atci, et al.
Published: (2025-04-01)

Research progress on the association of bullous pemphigoid with type 2 diabetes mellitus
by: ZHANG Ruohan, et al.
Published: (2025-03-01)

Pathogenesis, diagnosis and treatment of immune checkpoint inhibitor related bullous pemphigoid
by: Yi SUN, et al.
Published: (2025-04-01)

Ofatumumab for the management of refractory pemphigus vulgaris: A case series
by: Sera Sarsam, MBBS, BMedSc, et al.
Published: (2025-10-01)

Tense Bullous Eruptions Arising in Porokeratosis: A Quiz
by: Tomoko Hirano, et al.
Published: (2025-07-01)

Penetrating Keratoplasty For Treatment Of Bullous Keratopathy
by: Snezhana V. Murgova, et al.
Published: (2015-12-01)

Bullous mastocytosis: a Case Report
by: Galal El Enany, et al.
Published: (2024-05-01)

Rituximab in pemphigus and pemphigoid patients: Treatment outcomes and safety profile - A 6-year tertiary center study
by: Sivakanth Gopakumar, et al.
Published: (2025-07-01)